Abiopharma

🔍 Anand Kapila K (Executive)

Company: Elanco Animal Health Inc (ELAN)

Report Date: 2025-12-31

Detailed Transactions and Holdings:

• Acquired 381 shares of Deferred Stock Units (Derivative)
  Date: 2025-12-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 8,894.74 | transaction_form_type: 4 | Footnotes: F1, F3, F2, F1, F1

Footnotes:

• F1: Ms. Anand elected to defer her director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock.
• F2: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan.
• F3: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $22.63 on December 31, 2025.